The effect of one-week treatment with venlafaxine on 35% CO2 hyperreactivity in patients with panic disorder: An open study [6]

Journal of Clinical Psychopharmacology

Volumn 23, Issue 1, 2003, Pages 106-108

  Bertani, Angelo ^a   Bellodi, Laura ^a   Bussi, Riccardo ^a   Caldirola, Daniela ^a   Cucchi, Michele ^a   Perna, Giampaolo ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON DIOXIDE; PLACEBO; VENLAFAXINE;

ADULT; AGORAPHOBIA; ANXIETY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; HAMILTON SCALE; HUMAN; LETTER; MALE; MENTAL DISEASE; PANIC; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; QUESTIONNAIRE; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CARBON DIOXIDE; CYCLOHEXANOLS; HUMANS; PANIC DISORDER; PSYCHIATRIC STATUS RATING SCALES;

EID: 0037311199     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200302000-00020     Document Type: Letter

References (20)

1. Gorman JM, Fyer MR, Goetz R, et al. Ventilatory physiology of patients with panic disorder. Arch Gen Psychiatry 1988;45:31-9.
2. Griez E, de Loof C, Pols H, et al. Specific sensitivity of patients with panic attacks to carbon dioxide inhalation. Psychiatry Res 1990;31:193-9.
3. Perna G, Bertani A, Arancio C, et al. Laboratory response of patients with panic and obsessive-compulsive disorder to 35% CO2 challenges. Am J Psychiatry 1995;152:85-9.
4. Battaglia M and Perna G. The 35% CO2 challenge in panic disorder: optimization by Receiver Operating Characteristics (ROC) analysis. J Psychiatry Res 1995;29:111-9.
5. Perna G, Cocchi S, Bertani A, et al. Pharmacologic effect of toloxatone on reactivity to the 36% carbon dioxide challenge: a singleblind, random, placebo-controlled study. J Clin Psychopharmacol 1994;14:414-8.
6. Verburg K, Pols H, de Leeuw M, et al. Reliability of the 35% carbon dioxide panic challenge. Psychiatry Res 1998;78:207-14.
7. Bertani A, Perna G, Arancio C, et al. Pharmacologic effects of imipramine, paroxetine and sertraline on 35% Carbon dioxide hypersensitivity in patients with PD: a doubleblind, random, placebo-controlled study. J Clin Psychopharmacol 1997;17:97-101.
8. Perna G, Bertani A, Gabriele A, et al. Modification of 35% CO2 hypersensivity across one-week of treatment with clomipramine and fluvoxamine: a double-blind, randomized, placebo controlled study. J Clin Psychopharmacol 1997;17:173-8.
9. Pols H, Hauzer RC, Meijer JA, et al. Fluvoxamine attenuates 35% CO2 challenge-induced panic. J Clin Psychiatry 1996;57:539-42.
10. Perna G, Bertani A, Caldirola D et al. Antipanic drug modulation of 35% CO2 hyperreactivity and short-term treatment outcome. J Clin Psychopharmacol, in press.
11. van den Hout MA, Griez E. Panic symptoms after inhalation of carbon dioxide. Br. J Psychiatry 1984;144:503-7.
12. Geracioti TD Jr. Venlafaxine treatment of panic disorder: a case series. J Clin Psychiatry 1995;56:408-10.
13. Pollack MH, Worthington JJ 3rd, Otto MW, et al. Venlafaxine for panic disorder: results from a double-blind, placebo-controlled study. Psychopharmacol Bull 1996;32:667-70.
14. Papp LA, Sinha SS, Martinez JM, et al. Lowdose venlafaxine treatment in panic disorder. Psychopharmacol Bull 1998;34:207-9.
15. Argyle N, Deltito J, Allerup P, et al. The Panic-Associated Symptoms Scale: measuring the severity of panic disorder. Acta Psychiatr Scand 1991;83:20-6.
16. Marks IM, Mathews AM. Brief standard self-rating for phobic patients. Behaviour Research and Therapy 1979;17:263-7.
17. Hamilton M. The assessment of anxiety states by rating. Br J Medical Psychology 1959:32:50-55.
18. Spielberger CD, Gorsuch R, Lushere R. STAI Manual for the State-Trait Anxiety Inventory. Palo Alto 1970: Consulting Psychologists Press.
19. Muth EA, Haskins JT, Moyer JA, et al. Antidepressant biochemical profile of the novel bicyclic compound Wy-45, 030, an ethylcyclohexanol derivative. Biochem Pharmacol 1986;35:4493-7.
20. Bianchi AL, Denavit-Sauble M, Champagnant J. Central control of breathing in mammals: neuronal circuitry, membrane proprieties and neurotransmitters. Physiol Rev 1995;75:1-45.